Leadership

Rajiv Khosla, Ph.D.

Chief Executive Officer

Dr. Rajiv Khosla is Enteris BioPharma’s Chief Executive Officer. He joined the Company in April 2020, bringing more than 30 years of biopharmaceutical industry experience as both a consultant and senior corporate executive to the company. As CEO, Dr. Khosla leads the company in executing the strategy for Enteris to pursue multiple growth opportunities built on the company’s distinct core competencies in pharmaceutical product development.

Dr. Khosla founded CEUTEC LLC, a strategy and business development consultancy serving biopharmaceutical companies and venture capital firms. In that capacity, Dr. Khosla consulted with a variety of biopharmaceutical, drug delivery, and medical device companies to implement business strategies, 505(b)(2) product pipeline programs leading to successful FDA filings, and licensing transactions. Prior to CEUTEC, Dr. Khosla held several senior roles in large and small biopharmaceutical companies, most recently at the former Biovail Corp. as Vice President of Business Development. Dr. Khosla has served on the Boards of Orasi Medical, IntelGenx, and BioNJ.

Dr. Khosla received a Bachelor of Pharmacy with honors and a Ph.D. in Pharmaceutical Drug Delivery from the University of Nottingham in England. He earned an Executive M.B.A. from the Henley Business School at the University of Reading. Dr. Khosla is a member of the Royal Pharmaceutical Society of Great Britain.

Paul Shields, Ph.D.

Chief Operating Officer

Dr. Paul Shields is Enteris BioPharma's Chief Operating Officer. He joined the Company in July 2013, bringing more than 24 years of experience in the biopharmaceutical industry, focusing on Chemistry, Manufacturing and Controls (CMC) for a variety of products. As COO, Dr. Shields leads several operational and strategic initiatives crucial to the growth and expansion of Enteris.

Dr. Shields previously served as the Vice President, Manufacturing Operations for Unigene Laboratories from 2005 to 2013, where he managed commercial CMC operations for recombinant active ingredients, and clinical and commercial supplies of nasal spray and solid dose products. Prior to that, he served as Unigene’s Director of Plant Operations from 2001 through 2005, as Plant Manager from 1995 through 2001, and in various other capacities with Unigene from 1989 through 1995.

Dr. Shields holds a Ph.D. in biochemistry from the University of Pennsylvania and a B.S. in Chemical Engineering from the University of Michigan.

Gary A. Shangold, M.D.

Chief Medical Officer

Dr. Shangold is Enteris BioPharma’s Chief Medical Officer. He joined the Company in January 2020, bringing more than 30 years of pharmaceutical industry and consulting experience in clinical research and regulatory affairs. As CMO, Dr. Shangold is responsible for heading the clinical and regulatory strategy for Enteris pipeline initiatives.

Dr. Shangold is a seasoned industry professional having held C-suite level roles at a variety of innovative organizations. Prior to joining Enteris BioPharma, Dr. Shangold was the founder and CEO of InteguRx Therapeutics, a company developing transdermal pharmaceutical products. He was formerly Chief Medical Officer / Executive VP for R&D at Xanodyne Pharmaceuticals. Before that, he was President & CEO of NovaDel Pharma, a publicly-traded specialty pharma company. Earlier still, he worked at Johnson & Johnson Pharmaceutical R&D, where he held several senior roles in Clinical Research and Regulatory Affairs. Prior to J&J, Dr. Shangold was Medical Director of Ob/Gyn/Infertility at Serono Labs. Prior to joining industry, he served on the faculties of The University of Chicago Pritzker School of Medicine, Massachusetts General Hospital and the Harvard School of Medicine. Dr. Shangold is a Past President of the American Academy of Pharmaceutical Physicians and a former Board Chair of the Association of Clinical Research Professionals.

Dr. Shangold completed an Ob/Gyn residency at Jackson Memorial Hospital / University of Miami and a fellowship in Reproductive Endocrinology at the L.A. County / University of Southern California Medical Center. He received a BA in Social Behavior from the University of Pennsylvania, and an MD from the Columbia University College of Physicians and Surgeons.

Thomas Daggs, MBA

Vice President, Product Development & Quality Control

Mr. Daggs is Enteris BioPharma's Vice President of Product Development & Quality Control. He joined the Company in July 2013, bringing more than 18 years of experience in the biopharmaceutical industry, focusing primarily on drug product Chemistry, Manufacturing and Controls (CMC). As the Vice President of Product Development & Quality Control at Enteris, Mr. Daggs is responsible for the execution of CMC aspects of internal and client-led programs at Enteris.

Mr. Daggs previously served as the Director of Product Development & Quality Control for Unigene Laboratories from 2011 through 2013, where he managed analytical and CMC development of solid dose products. Prior to that, he served various levels of increasing responsibility at Unigene Laboratories from 2004 through 2011, and at Roche Molecular Systems from 2003 through 2004.

Mr. Daggs holds an MBA from Rutgers University and a B.S. in molecular biology from Montclair State University.

KNOWLEDGE CENTER

Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.

LEARN MORE

KNOWLEDGE CENTER

Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.

LEARN MORE